Nature Communications (Dec 2020)
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report
- Matthew S. Buckland,
- James B. Galloway,
- Caoimhe Nic Fhogartaigh,
- Luke Meredith,
- Nicholas M. Provine,
- Stuart Bloor,
- Ane Ogbe,
- Wioleta M. Zelek,
- Anna Smielewska,
- Anna Yakovleva,
- Tiffeney Mann,
- Laura Bergamaschi,
- Lorinda Turner,
- Frederica Mescia,
- Erik J. M. Toonen,
- Carl-Philipp Hackstein,
- Hossain Delowar Akther,
- Vinicius Adriano Vieira,
- Lourdes Ceron-Gutierrez,
- Jimstan Periselneris,
- Sorena Kiani-Alikhan,
- Sofia Grigoriadou,
- Devan Vaghela,
- Sara E. Lear,
- M. Estée Török,
- William L. Hamilton,
- Joanne Stockton,
- Josh Quick,
- Peter Nelson,
- Michael Hunter,
- Tanya I. Coulter,
- Lisa Devlin,
- CITIID-NIHR COVID-19 BioResource Collaboration,
- MRC-Toxicology Unit COVID-19 Consortium,
- John R. Bradley,
- Kenneth G. C. Smith,
- Willem H. Ouwehand,
- Lise Estcourt,
- Heli Harvala,
- David J. Roberts,
- Ian B. Wilkinson,
- Nick Screaton,
- Nicholas Loman,
- Rainer Doffinger,
- Paul A. Lyons,
- B. Paul Morgan,
- Ian G. Goodfellow,
- Paul Klenerman,
- Paul J. Lehner,
- Nicholas J. Matheson,
- James E. D. Thaventhiran
Affiliations
- Matthew S. Buckland
- Department of Clinical Immunology, Barts Health
- James B. Galloway
- Centre for Rheumatic Diseases, King’s College London
- Caoimhe Nic Fhogartaigh
- Department of Infection, Barts Health NHS Trust
- Luke Meredith
- Department of Pathology, University of Cambridge, Addenbrooke’s Hospital
- Nicholas M. Provine
- Peter Medawar Building for Pathogen Research
- Stuart Bloor
- Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus
- Ane Ogbe
- Peter Medawar Building for Pathogen Research
- Wioleta M. Zelek
- Systems Immunity Institute and Dementia Research Institute, Cardiff University
- Anna Smielewska
- Division of Virology, Department of Pathology, University of Cambridge, Addenbrookes Hospital
- Anna Yakovleva
- Department of Pathology, University of Cambridge, Addenbrooke’s Hospital
- Tiffeney Mann
- Medical Research Council Toxicology Unit, University of Cambridge
- Laura Bergamaschi
- Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus
- Lorinda Turner
- Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus
- Frederica Mescia
- Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus
- Erik J. M. Toonen
- R&D Department, Hycult Biotechnology
- Carl-Philipp Hackstein
- Peter Medawar Building for Pathogen Research
- Hossain Delowar Akther
- Peter Medawar Building for Pathogen Research
- Vinicius Adriano Vieira
- Peter Medawar Building for Pathogen Research
- Lourdes Ceron-Gutierrez
- Department of Clinical Biochemistry and Immunology, Addenbrooke’s Hospital
- Jimstan Periselneris
- Respiratory Department, King’s College Hospital NHS Foundation Trust, UK. Department of Clinical Virology
- Sorena Kiani-Alikhan
- Department of Clinical Immunology, Barts Health
- Sofia Grigoriadou
- Department of Clinical Immunology, Barts Health
- Devan Vaghela
- Department of Infectious Diseases, Cambridge University Hospitals NHS Trust
- Sara E. Lear
- Department of Immunology, Cambridge University Hospitals NHS Trust
- M. Estée Török
- Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus
- William L. Hamilton
- Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus
- Joanne Stockton
- Institute of Microbiology and Infection, University of Birmingham
- Josh Quick
- Institute of Microbiology and Infection, University of Birmingham
- Peter Nelson
- Belfast Health and Social Care Trust
- Michael Hunter
- Belfast Health and Social Care Trust
- Tanya I. Coulter
- Belfast Health and Social Care Trust
- Lisa Devlin
- Belfast Health and Social Care Trust
- CITIID-NIHR COVID-19 BioResource Collaboration
- MRC-Toxicology Unit COVID-19 Consortium
- John R. Bradley
- NIHR BioResource and NIHR Cambridge Biomedical Research Centre, Cambridge Biomedical Campus
- Kenneth G. C. Smith
- Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus
- Willem H. Ouwehand
- Department of Haematology, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus
- Lise Estcourt
- NHS Blood and Transplant
- Heli Harvala
- NHS Blood and Transplant
- David J. Roberts
- NHS Blood and Transplant
- Ian B. Wilkinson
- Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus
- Nick Screaton
- Radiology, Papworth Hospital
- Nicholas Loman
- Institute of Microbiology and Infection, University of Birmingham
- Rainer Doffinger
- Respiratory Department, King’s College Hospital NHS Foundation Trust, UK. Department of Clinical Virology
- Paul A. Lyons
- Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus
- B. Paul Morgan
- Systems Immunity Institute and Dementia Research Institute, Cardiff University
- Ian G. Goodfellow
- Department of Pathology, University of Cambridge, Addenbrooke’s Hospital
- Paul Klenerman
- Peter Medawar Building for Pathogen Research
- Paul J. Lehner
- Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus
- Nicholas J. Matheson
- Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus
- James E. D. Thaventhiran
- Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus
- DOI
- https://doi.org/10.1038/s41467-020-19761-2
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 11
Abstract
Remdesivir is under evaluation for treatment of COVID-19 in clinical trials. Here, the authors report results of remdesivir treatment in a patient with COVID-19 and the genetic antibody deficiency XLA. They show a temporally correlated clinical and virological response, suggesting that remdesivir can reduce SARS-CoV-2 replication in patients.
